Standard triple antiemetic therapy
Phase 3
Standard triple antiemetic therapy is one of 49 therapeutic programs targeting Breast Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Standard triple antiemetic therapy
SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Duragesic
CCephalon
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Bisphosphonate
AmgenPreclinical
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Neoplasms1 trial
Efficacy and Safety of Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Randomized Controlled Trial
Not yet recruiting·SSecond Affiliated Hospital, Zhejiang University, School of Medicine·Phase 2·NCT07848984·190 enrolled
Breast Cancer1 trial
A Phase III Randomized Controlled Trial of Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07761325·374 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]